Literature DB >> 1403231

The dose-response relationship with angiotensin converting enzyme inhibitors: effects on blood pressure and biochemical parameters.

K R Lees1.   

Abstract

UNLABELLED: CURRENT USAGE: Plasma angiotensin converting enzyme (ACE) inhibition and dose-response relationships during blood pressure reductions were compared for several marketed ACE inhibitor compounds. Both peak and trough responses are considered and contrasted. The presently recommended antihypertensive doses of enalapril, lisinopril, perindopril and ramipril appear to lie within the linear range of the antihypertensive dose-response relationship. For benazepril and captopril, the recommended doses may be in the flat, upper part of the relationship. RECOMMENDATIONS: The recommended doses for initiating antihypertensive therapy may still be excessive in patients at risk of heightened pharmacodynamic responses. Further studies are required to clarify the dose-response relationship for all of these compounds.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1403231

Source DB:  PubMed          Journal:  J Hypertens Suppl        ISSN: 0952-1178


  3 in total

1.  Redefining the ACE-inhibitor dose-response relationship: substantial blood pressure lowering after massive doses.

Authors:  G A Christie; C Lucas; D N Bateman; W S Waring
Journal:  Eur J Clin Pharmacol       Date:  2006-11-07       Impact factor: 2.953

2.  Pharmacokinetics and biochemical efficacy of idrapril calcium, a novel ACE inhibitor, after multiple oral administration in humans.

Authors:  P J Wyld; J Grant; A Lippi; M Criscuoli; G Del Re; A Subissi
Journal:  Br J Clin Pharmacol       Date:  1994-11       Impact factor: 4.335

3.  Metabolic effects of long-term angiotensin-converting enzyme inhibition with fosinopril in patients with essential hypertension: relationship to angiotensin-converting enzyme inhibition.

Authors:  R Reneland; P E Andersson; A Haenni; H Lithell
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.